We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

42 hedge funds and large institutions have $328M invested in Prevail Therapeutics Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 18

11% more funds holding

Funds holding: 38 → 42 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less capital invested

Capital invested by funds: $349M → $328M (-$21.3M)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Holders
42
Holders Change
+4
Holders Change %
+10.53%
% of All Funds
0.92%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
22
Increased
6
Reduced
8
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$7.03M
2
BlackRock
BlackRock
New York
+$3.91M
3
Bank of America
Bank of America
North Carolina
+$2.72M
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$2.38M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.79M

Top Sellers

Rank Fund Capital Flow
1
Fidelity International
Fidelity International
Bermuda
-$6.6M
2
DCM
Driehaus Capital Management
Illinois
-$3.35M
3
Millennium Management
Millennium Management
New York
-$1.47M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.4M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$170M – – –
RCM
2
RA Capital Management
Massachusetts
$41.3M +$7.03M +619,980 +23%
EC
3
EcoR1 Capital
California
$29.4M – – –
BC
4
Boxer Capital
California
$13.8M – – –
Citadel Advisors
5
Citadel Advisors
Florida
$13.1M -$1.32M -116,063 -10%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$10.7M +$623K +55,000 +7%
OFM
7
Omega Fund Management
Massachusetts
$8.21M – – –
BI
8
BVF Inc
California
$8.06M – – –
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$6.29M -$1.4M -123,158 -19%
BlackRock
10
BlackRock
New York
$5.46M +$3.91M +344,734 +345%
CI
11
Clal Insurance
Israel
$3.59M -$181K -16,000 -5%
Bank of America
12
Bank of America
North Carolina
$2.95M +$2.72M +240,260 +120,130%
Vanguard Group
13
Vanguard Group
Pennsylvania
$2.88M +$1.79M +157,556 +205%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$2.58M +$2.38M +210,071 New
LCM
15
Laurion Capital Management
New York
$1.25M -$1.11M -98,051 -49%
SFM
16
Sphera Funds Management
Israel
$1.11M -$461K -40,713 -31%
Northern Trust
17
Northern Trust
Illinois
$1.03M +$786K +69,386 +487%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1M +$925K +81,666 New
UBS Group
19
UBS Group
Switzerland
$952K -$119K -10,485 Closed
DCM
20
DAFNA Capital Management
California
$921K – – –
State Street
21
State Street
Massachusetts
$763K +$704K +62,119 New
Millennium Management
22
Millennium Management
New York
$618K -$1.47M -129,915 -72%
AS
23
Altshuler Shaham
Israel
$615K +$572K +50,460 New
N
24
Nuveen
North Carolina
$299K +$277K +24,407 New
Charles Schwab
25
Charles Schwab
California
$193K +$177K +15,662 New
1
2 3

PRVL Hedge Fund Activity: Q3 2019 in Review

42 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q3 2019, worth a combined $328M — down 6.1% from $349M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PRVL positions and 18 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was RA Capital Management, adding an estimated $7.03M. The largest seller was Fidelity International, exiting entirely with an estimated $6.6M sold.

  • 42 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q3 2019, up from 38 in Q2 2019.
  • Funds reported $328M of Prevail Therapeutics Inc. Common Stock stock for Q3 2019, down 6.1% quarter-over-quarter.
  • 22 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q3 2019 and 18 closed out, a net change of +4 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q3 2019 was RA Capital Management, an estimated $7.03M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q3 2019 was Fidelity International, an estimated $6.6M sold.

Based on aggregated 13F filings for Q3 2019.